A sequential approach including bortezomib induction, intermediate-dose melphalan, and autologous stem cell transplantation (ASCT), followed by lenalidomide consolidation-maintenance, has been evaluated. Efficacy and safety data have been analyzed on intention-to-treat and results updated. Newly diagnosed myeloma patients 65 to 75 years of age (n = 102) received 4 cycles of bortezomib-pegylated liposomal doxorubicin-dexamethasone, tandem melphalan (100 mg/m(2)) followed by ASCT (MEL100-ASCT), 4 cycles of lenalidomide-prednisone consolidation (LP), and lenalidomide maintenance (L) until disease progression. The complete response (CR) rate was 33% after MEL100-ASCT, 48% after LP and 53% after L maintenance. After a median follow-up of 66 months, median time-to-progression (TTP) was 55 months and median progression-free survival 48 months. Median overall survival (OS) was not reached, 5-year OS was 63%. In CR patients, median TTP was 70 months and 5-year OS was 83%. Median survival from relapse was 28 months. Death related to adverse events (AEs) occurred in 8/102 patients during induction or transplantation. Rate of death related to AEs was higher in patients ≥70 years compared with younger (5/26 vs 3/76, P = .024). Bortezomib-induction followed by ASCT and lenalidomide consolidation-maintenance is a valuable option for elderly myeloma patients, with the greatest benefit in those younger than 70 years of age.

Bortezomib induction, reduced-intensity transplantation and lenalidomide consolidation-maintenance for myeloma: updated results / Gay, F; Magarotto, V; Crippa, C; Pescosta, N; Guglielmelli, T; Cavallo, F; Pezzatti, S; Ferrari, S; Liberati, Am; Oliva, S; Patriarca, F; Offidani, M; Omedé, P; Montefusco, V; Petrucci, Mt; Giuliani, Nicola; Passera, R; Pietrantuono, G; Boccadoro, M; Corradini, P; Palumbo, A.. - In: BLOOD. - ISSN 0006-4971. - 122:(2013), pp. 1376-1383. [10.1182/blood-2013-02483073]

Bortezomib induction, reduced-intensity transplantation and lenalidomide consolidation-maintenance for myeloma: updated results

GIULIANI, Nicola;
2013-01-01

Abstract

A sequential approach including bortezomib induction, intermediate-dose melphalan, and autologous stem cell transplantation (ASCT), followed by lenalidomide consolidation-maintenance, has been evaluated. Efficacy and safety data have been analyzed on intention-to-treat and results updated. Newly diagnosed myeloma patients 65 to 75 years of age (n = 102) received 4 cycles of bortezomib-pegylated liposomal doxorubicin-dexamethasone, tandem melphalan (100 mg/m(2)) followed by ASCT (MEL100-ASCT), 4 cycles of lenalidomide-prednisone consolidation (LP), and lenalidomide maintenance (L) until disease progression. The complete response (CR) rate was 33% after MEL100-ASCT, 48% after LP and 53% after L maintenance. After a median follow-up of 66 months, median time-to-progression (TTP) was 55 months and median progression-free survival 48 months. Median overall survival (OS) was not reached, 5-year OS was 63%. In CR patients, median TTP was 70 months and 5-year OS was 83%. Median survival from relapse was 28 months. Death related to adverse events (AEs) occurred in 8/102 patients during induction or transplantation. Rate of death related to AEs was higher in patients ≥70 years compared with younger (5/26 vs 3/76, P = .024). Bortezomib-induction followed by ASCT and lenalidomide consolidation-maintenance is a valuable option for elderly myeloma patients, with the greatest benefit in those younger than 70 years of age.
2013
Bortezomib induction, reduced-intensity transplantation and lenalidomide consolidation-maintenance for myeloma: updated results / Gay, F; Magarotto, V; Crippa, C; Pescosta, N; Guglielmelli, T; Cavallo, F; Pezzatti, S; Ferrari, S; Liberati, Am; Oliva, S; Patriarca, F; Offidani, M; Omedé, P; Montefusco, V; Petrucci, Mt; Giuliani, Nicola; Passera, R; Pietrantuono, G; Boccadoro, M; Corradini, P; Palumbo, A.. - In: BLOOD. - ISSN 0006-4971. - 122:(2013), pp. 1376-1383. [10.1182/blood-2013-02483073]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2651663
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 68
  • ???jsp.display-item.citation.isi??? 74
social impact